Why AI matters at this scale

Organon is a global pharmaceutical company with over 10,000 employees, focused on improving women's health and providing established medicines across therapeutic areas. As a large, publicly-traded entity spun off from Merck, it operates at a scale where efficiency gains and innovation acceleration directly impact competitive advantage and shareholder value. The pharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and complex global supply chains. For a company of Organon's size and strategic focus, AI is not a speculative technology but a critical lever to reduce operational risk, compress time-to-market for new therapies, and optimize the commercial performance of its portfolio.

Concrete AI Opportunities with ROI Framing

1. Accelerating Women's Health R&D: Clinical trials in women's health often face unique recruitment and endpoint challenges. AI can analyze diverse datasets, including real-world evidence and genomic data, to identify optimal patient populations and predict trial outcomes. This can reduce clinical development costs by millions per program and shorten timelines by months, directly boosting pipeline valuation and enabling faster delivery of needed therapies.

2. Optimizing Global Supply Chain Resilience: Organon's portfolio includes many essential medicines with complex manufacturing and distribution needs. Machine learning models can forecast demand with greater accuracy by incorporating variables like regional disease incidence, competitor actions, and logistical disruptions. This optimization can decrease inventory carrying costs by 10-20% and significantly reduce the risk of stock-outs, protecting revenue and patient access.

3. Enhancing Pharmacovigilance and Medical Affairs: Monitoring drug safety is a massive, manual data review process. Natural Language Processing (NLP) can automate the scanning of millions of adverse event reports, scientific literature, and social media mentions, flagging potential safety signals earlier. This improves regulatory compliance, reduces manual labor costs, and potentially mitigates future liability risks by enabling proactive responses.

Deployment Risks Specific to Large Enterprises

Implementing AI at Organon's scale carries specific risks. First, data integration is a monumental challenge, as information is often siloed across legacy systems from its Merck heritage, different ERPs, and clinical platforms. Second, regulatory scrutiny in pharma is intense; any AI model used in GxP processes (Good Clinical/Laboratory/Manufacturing Practices) requires rigorous validation and audit trails, slowing deployment. Third, change management in a large, science-driven organization can be difficult, as researchers and clinicians may be skeptical of "black box" models. Finally, the talent gap is acute; attracting and retaining top AI/ML scientists who also understand biology and regulatory science is expensive and competitive. Success requires a clear strategy that pairs pilot projects with strong executive sponsorship and close collaboration between data science, IT, and business units to ensure solutions are scalable, compliant, and truly address core business problems.